CompletedNot Applicable

The Resting-state EEG Gamma Oscillations in Alzheimer's Disease

Turkey (Türkiye)51 participantsStarted 2012-11-07

Plain-language summary

The literature suggests a strong association between amyloid accumulation and gamma alterations, emerging gamma activity as a biomarker candidate for Alzheimer's pathology. The present study aims to investigate resting-state gamma activity changes in Cerebrospinal fluid (CSF)-proven early-onset Alzheimer's disease (EOAD) patients with a holistic approach that employs structural and functional brain neuroimaging techniques, and neuropsychological aspects.

Who can participate

Age range

65 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * For all participants: Age \< 65 * For EOAD patients: Meeting National Institute on Aging-Alzheimer's Association diagnostic criteria. * For healthy controls: Mini-Mental State Examination (MMSE) \>25 Instrumental Activities of Daily Living Scale (IADL) = 8 Exclusion Criteria: * For EOAD patients: MMSE \> 24 Geriatric depression scale (GDS) \> 14 Having treatment with antipsychotics and comorbidities that may affect cognitive abilities. * For healthy controls: Having neurological and/or cognitive abnormalities Having a history of neurological, psychiatric, or systemic disorders, and alcohol/drug abuse. GDS \> 14 * For all participants: Having neurological (other than AD) or any other serious disease (cancer, systemic disease)

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

EEG

Timeframe: Day 2

Trial details

NCT IDNCT05989087

SponsorGörsev Yener, MD, PhD

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2016-01-02

View on ClinicalTrials.gov More Alzheimer Disease, Early Onset trials